Proton pump inhibitors (PPIs) and hypomagnesaemia
- prolonged use of proton pump inhibitors (PPIs) has been associated with case reports of hypomagnesaemia
- some cases occurred after 3 months of PPI therapy, but most occurred after 1 year of treatment
- serious manifestations of hypomagnesaemia - fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia - can occur, but they may begin insidiously and be overlooked. In most case reports, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI
- serious manifestations of hypomagnesaemia - fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia - can occur, but they may begin insidiously and be overlooked. In most case reports, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI
- some cases occurred after 3 months of PPI therapy, but most occurred after 1 year of treatment
- healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment, especially in those who will take a PPI concomitantly with digoxin or drugs that may cause hypomagnesaemia (eg, diuretics)
The MHRA advise that healthcare professionals should:
- consider measurement of magnesium levels before starting PPI treatment and periodically during prolonged treatment, especially in those who will take a PPI concomitantly with digoxin or drugs that may cause hypomagnesaemia (eg, diuretics)
- take into account any use of PPIs obtained over-the-counter
Reference:
Related pages
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page